iX Biopharma Ltd. (SGX:42C)

iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 103.99 million. The enterprise value is 108.96 million.

Market Cap	103.99M
Enterprise Value	108.96M

Important Dates

The next estimated earnings date is Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

iX Biopharma has 888.84 million shares outstanding. The number of shares has increased by 14.25% in one year.

Current Share Class	888.84M
Shares Outstanding	888.84M
Shares Change (YoY)	+14.25%
Shares Change (QoQ)	+1.06%
Owned by Insiders (%)	44.23%
Owned by Institutions (%)	0.11%
Float	463.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.39
PB Ratio	284.92
P/TBV Ratio	1,094.68
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-10.74
EV / Sales	14.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.52

Financial Position

The company has a current ratio of 0.47, with a Debt / Equity ratio of 16.17.

Current Ratio	0.47
Quick Ratio	0.32
Debt / Equity	16.17
Debt / EBITDA	n/a
Debt / FCF	-1.49
Interest Coverage	-18.99

Financial Efficiency

Return on equity (ROE) is -431.07% and return on invested capital (ROIC) is -49.70%.

Return on Equity (ROE)	-431.07%
Return on Assets (ROA)	-30.32%
Return on Invested Capital (ROIC)	-49.70%
Return on Capital Employed (ROCE)	-272.67%
Revenue Per Employee	221,914
Profits Per Employee	-289,743
Employee Count	35
Asset Turnover	0.60
Inventory Turnover	4.98

Taxes

In the past 12 months, iX Biopharma has paid 1,000 in taxes.

Income Tax	1,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +372.00% in the last 52 weeks. The beta is 0.31, so iX Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	+372.00%
50-Day Moving Average	0.05
200-Day Moving Average	0.03
Relative Strength Index (RSI)	75.51
Average Volume (20 Days)	20,589,880

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 7.77 million and -10.14 million in losses. Loss per share was -0.01.

Revenue	7.77M
Gross Profit	2.04M
Operating Income	-6.29M
Pretax Income	-10.14M
Net Income	-10.14M
EBITDA	-5.87M
EBIT	-6.29M
Loss Per Share	-0.01

Balance Sheet

The company has 935,000 in cash and 5.90 million in debt, giving a net cash position of -4.97 million or -0.01 per share.

Cash & Cash Equivalents	935,000
Total Debt	5.90M
Net Cash	-4.97M
Net Cash Per Share	-0.01
Equity (Book Value)	365,000
Book Value Per Share	0.00
Working Capital	-4.77M

Cash Flow

In the last 12 months, operating cash flow was -3.76 million and capital expenditures -201,000, giving a free cash flow of -3.96 million.

Operating Cash Flow	-3.76M
Capital Expenditures	-201,000
Free Cash Flow	-3.96M
FCF Per Share	-0.00

Margins

Gross margin is 26.26%, with operating and profit margins of -80.92% and -130.57%.

Gross Margin	26.26%
Operating Margin	-80.92%
Pretax Margin	-130.55%
Profit Margin	-130.57%
EBITDA Margin	-75.59%
EBIT Margin	-80.92%
FCF Margin	n/a

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.25%
Shareholder Yield	n/a
Earnings Yield	-9.75%
FCF Yield	-3.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

iX Biopharma has an Altman Z-Score of -13.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.82
Piotroski F-Score	4